Atika Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Atika Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,500	Closed	-$3.88M	–	95
2023 Q1	$3.88M	Sell	26,500 -62,907	-70%	-$9.31M	0.57%	54
2022 Q4	$14.2M	Sell	89,407 -40,593	-31%	-$5.95M	2.05%	16
2022 Q3	$17.3M	Sell	130,000 -39,000	-23%	-$5.93M	1.47%	23
2022 Q2	$26.4M	Sell	169,000 -30,000	-15%	-$4.62M	2.96%	6
2022 Q1	$31M	Buy	+199,000	New	+$28.9M	2.61%	9
2017 Q4	–	Sell	-14,500	Closed	-$2.12M	–	75
2017 Q3	$2.12M	Sell	14,500 -4,000	-22%	-$605K	0.61%	59
2017 Q2	$2.88M	Buy	18,500 +3,500	+23%	+$535K	1.01%	38
2017 Q1	$2.18M	Buy	+15,000	New	+$1.95M	1.07%	45
2015 Q3	–	Sell	-17,000	Closed	-$2.99M	–	73
2015 Q2	$2.99M	Buy	17,000 +3,400	+25%	+$611K	1.35%	32
2015 Q1	$2.35M	Buy	13,600 +6,500	+92%	+$1.12M	1.57%	30
2014 Q4	$1.16M	Sell	7,100 -6,900	-49%	-$1.15M	0.85%	46
2014 Q3	$2.25M	Buy	+14,000	New	+$2.15M	1.73%	24
2014 Q1	–	Sell	-16,650	Closed	-$2.11M	–	65
2013 Q4	$2.11M	Buy	+16,650	New	+$1.72M	1.87%	21

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Atika Capital Management's JAZZ Position: Q2 2023 in Review

Atika Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 26,500 shares — an estimated $3.88M sold.

Atika Capital Management first reported a position in JAZZ in Q4 2013 and held it in 13 quarters. The position peaked at $31M in Q1 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Atika Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Atika Capital Management sold 26,500 Jazz Pharmaceuticals shares in Q2 2023, an estimated $3.88M.
Atika Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 13 quarters.
Atika Capital Management's Jazz Pharmaceuticals position peaked at $31M in Q1 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Atika Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.